Symbols / CDNA
CDNA Chart
About
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI, a transplant quality tracking software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 982.57M |
| Enterprise Value | 823.51M | Income | 70.45M | Sales | 358.00M |
| Book/sh | 6.05 | Cash/sh | 3.78 | Dividend Yield | — |
| Payout | 0.00% | Employees | 644 | IPO | — |
| P/E | 14.42 | Forward P/E | 16.41 | PEG | — |
| P/S | 2.74 | P/B | 3.05 | P/C | — |
| EV/EBITDA | -56.13 | EV/Sales | 2.30 | Quick Ratio | 2.44 |
| Current Ratio | 3.03 | Debt/Eq | 8.88 | LT Debt/Eq | — |
| EPS (ttm) | 1.28 | EPS next Y | 1.12 | EPS Growth | — |
| Revenue Growth | 20.70% | Earnings | 2026-04-29 | ROA | -4.01% |
| ROE | 24.11% | ROIC | — | Gross Margin | 67.64% |
| Oper. Margin | -0.25% | Profit Margin | 19.68% | Shs Outstand | 51.43M |
| Shs Float | 49.93M | Short Float | 11.46% | Short Ratio | 7.76 |
| Short Interest | — | 52W High | 22.95 | 52W Low | 10.96 |
| Beta | 2.51 | Avg Volume | 726.65K | Volume | 1.44M |
| Target Price | $23.33 | Recom | Buy | Prev Close | $19.25 |
| Price | $18.46 | Change | -4.10% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$23.33
Mean price target
2. Current target
$18.46
Latest analyst target
3. DCF / Fair value
$15.13
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$18.46
Low
$18.00
High
$28.00
Mean
$23.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-25 | main | Wells Fargo | Equal-Weight → Equal-Weight | $21 |
| 2025-12-15 | main | Wells Fargo | Equal-Weight → Equal-Weight | $18 |
| 2025-11-06 | main | BTIG | Buy → Buy | $25 |
| 2025-09-23 | reit | BTIG | Buy → Buy | $22 |
| 2025-09-12 | reit | BTIG | Buy → Buy | $22 |
| 2025-08-26 | init | William Blair | — → Market Perform | — |
| 2025-08-08 | main | Wells Fargo | Equal-Weight → Equal-Weight | $14 |
| 2025-07-18 | main | Craig-Hallum | Buy → Buy | $26 |
| 2025-05-05 | reit | Stephens & Co. | Overweight → Overweight | $40 |
| 2025-05-05 | reit | HC Wainwright & Co. | Neutral → Neutral | $25 |
| 2025-04-17 | main | Goldman Sachs | Buy → Buy | $26 |
| 2025-03-03 | main | HC Wainwright & Co. | Neutral → Neutral | $25 |
| 2025-02-27 | reit | Stephens & Co. | Overweight → Overweight | $40 |
| 2025-01-15 | up | Wells Fargo | Underweight → Equal-Weight | $24 |
| 2025-01-14 | reit | HC Wainwright & Co. | Neutral → Neutral | $26 |
| 2024-11-05 | main | BTIG | Buy → Buy | $35 |
| 2024-10-22 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-10-16 | main | Goldman Sachs | Buy → Buy | $35 |
| 2024-08-27 | init | Wells Fargo | — → Underweight | $28 |
| 2024-08-19 | up | BTIG | Neutral → Buy | $40 |
- CareDx (CDNA) Receives Rating Update: Wells Fargo Raises Price T - GuruFocus Wed, 25 Feb 2026 16
- BTIG raises CareDx stock price target to $26 on strong Q4 results - Investing.com Nigeria Wed, 25 Feb 2026 22
- One executive will run CareDx operations and finances from Feb. 26 - Stock Titan ue, 24 Feb 2026 22
- CareDx (CDNA) Q4 Earnings Miss Estimates - Yahoo Finance Wed, 25 Feb 2026 00
- CareDx: Conservative Revenue Upside Offset by Weaker Margins and Coverage Uncertainty Justifying Hold Rating - TipRanks Wed, 25 Feb 2026 16
- AlloHeme Clinical Validation Could Be A Game Changer For CareDx’s (CDNA) Transplant Platform Expansion - simplywall.st Mon, 23 Feb 2026 00
- CareDx Inc (NASDAQ:CDNA) Reports Strong Revenue Beat but Profitability Concerns Weigh on Shares - ChartMill ue, 24 Feb 2026 23
- AlloHeme Clinical Validation Could Be A Game Changer For CareDx’s (CDNA) Transplant Platform Expansion - Sahm Mon, 23 Feb 2026 08
- CareDx Q4 2025 Earnings Call Transcript - MarketBeat Wed, 25 Feb 2026 06
- Insider Sale: President and CEO of $CDNA Sells 200 Shares - Quiver Quantitative Fri, 23 Jan 2026 08
- Wells Fargo Maintains CareDx(CDNA.US) With Hold Rating, Raises Target Price to $21 - 富途牛牛 Wed, 25 Feb 2026 16
- CareDx (CDNA) Reports Q4 Earnings: What Key Metrics Have to Say - Nasdaq Wed, 25 Feb 2026 01
- CareDx heads to Raymond James gathering of big investors - Stock Titan Wed, 18 Feb 2026 13
- CareDx sets Feb. 24 webcast for Q4 and full-year 2025 results - Stock Titan ue, 10 Feb 2026 08
- CareDx Names New CFO Amid Strong Q4 2025 Results - TipRanks ue, 24 Feb 2026 21
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4441 | 91286 | — | Sale at price 20.56 per share. | NOVACK JEFFREY ADAM | General Counsel | — | 2026-02-03 00:00:00 | D |
| 1 | 200132 | — | — | Stock Award(Grant) at price 0.00 per share. | HANNA JOHN WALTER JR | Chief Executive Officer | — | 2026-02-02 00:00:00 | D |
| 2 | 37342 | — | — | Stock Award(Grant) at price 0.00 per share. | NOVACK JEFFREY ADAM | General Counsel | — | 2026-02-02 00:00:00 | D |
| 3 | 71579 | — | — | Stock Award(Grant) at price 0.00 per share. | MENG JESSICA | Officer | — | 2026-02-02 00:00:00 | D |
| 4 | 40875 | — | — | Stock Award(Grant) at price 0.00 per share. | SMITH NATHAN | Chief Financial Officer | — | 2026-02-02 00:00:00 | D |
| 5 | 74474 | — | — | Stock Award(Grant) at price 0.00 per share. | KENNEDY KEITH S | Chief Operating Officer | — | 2026-02-02 00:00:00 | D |
| 6 | 19480 | 412223 | — | Sale at price 21.00 - 21.16 per share. | HANNA JOHN WALTER JR | Chief Executive Officer | — | 2026-01-22 00:00:00 | D |
| 7 | 10156 | 213804 | — | Sale at price 21.05 per share. | HANNA JOHN WALTER JR | Chief Executive Officer | — | 2026-01-15 00:00:00 | D |
| 8 | 1492 | — | — | Stock Award(Grant) at price 0.00 per share. | GOLDBERG MICHAEL D | Director | — | 2026-01-06 00:00:00 | D |
| 9 | 7293 | 139804 | — | Sale at price 19.15 - 19.75 per share. | NOVACK JEFFREY ADAM | General Counsel | — | 2025-12-04 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 567.10K | -20.71M | 22.47K | 4.66K |
| TaxRateForCalcs | 0.01 | 0.21 | 0.21 | 0.04 |
| NormalizedEBITDA | -128.51M | 13.69M | -61.33M | -17.95M |
| TotalUnusualItems | 94.52M | -98.61M | 107.00K | 106.00K |
| TotalUnusualItemsExcludingGoodwill | 94.52M | -98.61M | 107.00K | 106.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | 52.55M | -190.28M | -76.61M | -30.66M |
| ReconciledDepreciation | 19.76M | 19.82M | 16.01M | 11.88M |
| ReconciledCostOfRevenue | 109.63M | 102.00M | 112.21M | 97.39M |
| EBITDA | -33.99M | -84.92M | -61.22M | -17.84M |
| EBIT | -53.75M | -104.74M | -77.23M | -29.73M |
| NetInterestIncome | 11.77M | 11.87M | 3.76M | 160.00K |
| InterestIncome | 11.77M | 11.87M | 3.76M | 160.00K |
| NormalizedIncome | -41.40M | -112.38M | -76.70M | -30.76M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 52.55M | -190.28M | -76.61M | -30.66M |
| TotalExpenses | 387.54M | 385.07M | 399.02M | 326.12M |
| TotalOperatingIncomeAsReported | 40.77M | -203.36M | -77.23M | -29.73M |
| DilutedAverageShares | 56.62M | 53.76M | 53.32M | 52.24M |
| BasicAverageShares | 52.77M | 53.76M | 53.32M | 52.24M |
| DilutedEPS | 0.93 | -3.54 | -1.44 | -0.59 |
| BasicEPS | 1.00 | -3.54 | -1.44 | -0.59 |
| DilutedNIAvailtoComStockholders | 52.55M | -190.28M | -76.61M | -30.66M |
| NetIncomeCommonStockholders | 52.55M | -190.28M | -76.61M | -30.66M |
| NetIncome | 52.55M | -190.28M | -76.61M | -30.66M |
| NetIncomeIncludingNoncontrollingInterests | 52.55M | -190.28M | -76.61M | -30.66M |
| NetIncomeContinuousOperations | 52.55M | -190.28M | -76.61M | -30.66M |
| TaxProvision | 310.00K | 141.00K | 379.00K | -1.43M |
| PretaxIncome | 52.86M | -190.14M | -76.23M | -32.09M |
| OtherIncomeExpense | 94.85M | -97.27M | -2.77M | -2.52M |
| OtherNonOperatingIncomeExpenses | 329.00K | 1.34M | -2.87M | -2.63M |
| SpecialIncomeCharges | 94.52M | -98.62M | 0.00 | 0.00 |
| OtherSpecialCharges | -96.30M | 96.30M | ||
| RestructuringAndMergernAcquisition | 1.78M | 2.32M | 0.00 | 0.00 |
| GainOnSaleOfSecurity | 10.00K | 107.00K | 106.00K | |
| NetNonOperatingInterestIncomeExpense | 11.77M | 11.87M | 3.76M | 160.00K |
| InterestIncomeNonOperating | 11.77M | 11.87M | 3.76M | 160.00K |
| OperatingIncome | -53.75M | -104.74M | -77.23M | -29.73M |
| OperatingExpense | 277.91M | 283.07M | 286.81M | 228.73M |
| ResearchAndDevelopment | 72.41M | 81.87M | 90.39M | 76.53M |
| SellingGeneralAndAdministration | 205.50M | 201.20M | 196.42M | 152.21M |
| SellingAndMarketingExpense | 81.72M | 83.33M | 96.03M | 77.25M |
| GeneralAndAdministrativeExpense | 123.78M | 117.87M | 100.40M | 74.96M |
| OtherGandA | 123.78M | 117.87M | 100.40M | 74.96M |
| GrossProfit | 224.16M | 178.32M | 209.58M | 199.01M |
| CostOfRevenue | 109.63M | 102.00M | 112.21M | 97.39M |
| TotalRevenue | 333.79M | 280.32M | 321.79M | 296.40M |
| OperatingRevenue | 333.79M | 280.32M | 321.79M | 296.40M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 54.77M | 51.50M | 53.53M | 52.92M |
| ShareIssued | 54.77M | 51.50M | 53.53M | 52.92M |
| TotalDebt | 28.37M | 34.22M | 39.00M | 21.35M |
| TangibleBookValue | 299.91M | 175.29M | 350.34M | 378.70M |
| InvestedCapital | 378.43M | 261.33M | 430.91M | 465.88M |
| WorkingCapital | 262.46M | 235.64M | 311.87M | 356.06M |
| NetTangibleAssets | 299.91M | 175.29M | 350.34M | 378.70M |
| CapitalLeaseObligations | 28.37M | 34.22M | 39.00M | 21.35M |
| CommonStockEquity | 378.43M | 261.33M | 430.91M | 465.88M |
| TotalCapitalization | 378.43M | 261.33M | 430.91M | 465.88M |
| TotalEquityGrossMinorityInterest | 378.43M | 261.33M | 430.91M | 465.88M |
| StockholdersEquity | 378.43M | 261.33M | 430.91M | 465.88M |
| GainsLossesNotAffectingRetainedEarnings | -8.57M | -6.96M | -7.50M | -4.67M |
| OtherEquityAdjustments | -8.57M | -6.96M | -7.50M | -4.67M |
| RetainedEarnings | -626.24M | -678.27M | -460.44M | -383.19M |
| AdditionalPaidInCapital | 1.01B | 946.51M | 898.81M | 853.68M |
| CapitalStock | 51.00K | 49.00K | 52.00K | 52.00K |
| CommonStock | 51.00K | 49.00K | 52.00K | 52.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 112.62M | 205.50M | 112.08M | 100.75M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 23.25M | 127.43M | 36.10M | 23.44M |
| OtherNonCurrentLiabilities | 819.00K | 99.01M | 249.00K | 455.00K |
| DerivativeProductLiabilities | 0.00 | 32.00K | 139.00K | |
| NonCurrentDeferredLiabilities | 164.00K | 136.00K | 2.42M | 5.46M |
| NonCurrentDeferredTaxesLiabilities | 164.00K | 136.00K | 0.00 | 415.00K |
| LongTermDebtAndCapitalLeaseObligation | 22.26M | 28.28M | 33.41M | 17.39M |
| LongTermCapitalLeaseObligation | 22.26M | 28.28M | 33.41M | 17.39M |
| CurrentLiabilities | 89.37M | 78.07M | 75.97M | 77.30M |
| OtherCurrentLiabilities | 2.54M | 5.62M | 2.34M | 4.73M |
| CurrentDeferredLiabilities | 5.10M | 5.67M | 7.40M | 6.21M |
| CurrentDeferredRevenue | 4.85M | 4.75M | 5.34M | 4.21M |
| CurrentDebtAndCapitalLeaseObligation | 6.10M | 5.94M | 5.59M | 3.96M |
| CurrentCapitalLeaseObligation | 6.10M | 5.94M | 5.59M | 3.96M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 38.33M | 19.70M | 16.90M | 26.04M |
| PayablesAndAccruedExpenses | 37.30M | 41.14M | 43.74M | 36.37M |
| CurrentAccruedExpenses | 29.61M | 28.27M | 33.80M | 23.03M |
| Payables | 7.69M | 12.87M | 9.94M | 13.34M |
| AccountsPayable | 7.69M | 12.87M | 9.94M | 13.34M |
| TotalAssets | 491.05M | 466.83M | 542.99M | 566.62M |
| TotalNonCurrentAssets | 139.22M | 153.11M | 155.14M | 133.26M |
| OtherNonCurrentAssets | 2.81M | 1.94M | 4.35M | 6.05M |
| GoodwillAndOtherIntangibleAssets | 78.52M | 86.04M | 80.57M | 87.18M |
| OtherIntangibleAssets | 38.18M | 45.70M | 43.05M | 50.20M |
| Goodwill | 40.34M | 40.34M | 37.52M | 36.98M |
| NetPPE | 57.89M | 65.14M | 70.22M | 40.04M |
| AccumulatedDepreciation | -36.94M | -32.26M | -24.42M | -19.58M |
| GrossPPE | 94.83M | 97.40M | 94.64M | 59.62M |
| Leases | 18.11M | 18.26M | 17.39M | 8.47M |
| ConstructionInProgress | 11.94M | 8.31M | 7.64M | 10.93M |
| OtherProperties | 24.34M | 29.89M | 34.69M | 17.99M |
| MachineryFurnitureEquipment | 40.45M | 40.94M | 34.92M | 22.23M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 351.83M | 313.71M | 387.85M | 433.36M |
| OtherCurrentAssets | 7.07M | 7.76M | 9.22M | 7.93M |
| PrepaidAssets | 7.93M | |||
| Inventory | 19.50M | 19.47M | 19.23M | 17.19M |
| FinishedGoods | 4.82M | 3.66M | 2.96M | 3.91M |
| WorkInProcess | 3.79M | 5.19M | 4.31M | 2.83M |
| RawMaterials | 10.89M | 10.62M | 11.96M | 10.45M |
| Receivables | 64.61M | 51.06M | 66.31M | 59.76M |
| AccountsReceivable | 64.61M | 51.06M | 66.31M | 59.76M |
| CashCashEquivalentsAndShortTermInvestments | 260.65M | 235.42M | 293.09M | 348.49M |
| OtherShortTermInvestments | 145.96M | 153.22M | 203.17M | 0.00 |
| CashAndCashEquivalents | 114.69M | 82.20M | 89.92M | 348.49M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 31.56M | -27.63M | -49.57M | -39.55M |
| RepurchaseOfCapitalStock | -522.00K | -27.54M | -642.00K | 0.00 |
| RepaymentOfDebt | 0.00 | 0.00 | -66.00K | |
| IssuanceOfCapitalStock | 0.00 | 0.00 | 188.85M | |
| CapitalExpenditure | -6.48M | -9.24M | -24.33M | -20.26M |
| InterestPaidSupplementalData | 0.00 | 0.00 | 8.00K | 1.00K |
| IncomeTaxPaidSupplementalData | 317.00K | 738.00K | 392.00K | 14.00K |
| EndCashPosition | 115.27M | 82.78M | 90.44M | 348.70M |
| BeginningCashPosition | 82.78M | 90.44M | 348.70M | 134.94M |
| EffectOfExchangeRateChanges | 532.00K | -112.00K | 23.00K | -303.00K |
| ChangesInCash | 31.96M | -7.55M | -258.28M | 214.06M |
| FinancingCashFlow | -5.61M | -29.61M | -4.54M | 185.64M |
| CashFlowFromContinuingFinancingActivities | -5.61M | -29.61M | -4.54M | 185.64M |
| NetOtherFinancingCharges | -15.42M | -3.68M | -8.56M | -18.07M |
| ProceedsFromStockOptionExercised | 10.33M | 1.62M | 4.67M | 14.92M |
| NetCommonStockIssuance | -522.00K | -27.54M | -642.00K | 188.85M |
| CommonStockPayments | -522.00K | -27.54M | -642.00K | 0.00 |
| CommonStockIssuance | 0.00 | 0.00 | 188.85M | |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | -66.00K | |
| NetLongTermDebtIssuance | 0.00 | 0.00 | -66.00K | |
| LongTermDebtPayments | 0.00 | 0.00 | -66.00K | |
| InvestingCashFlow | -483.00K | 40.45M | -228.50M | 47.71M |
| CashFlowFromContinuingInvestingActivities | -483.00K | 40.45M | -228.50M | 47.71M |
| NetInvestmentPurchaseAndSale | 6.00M | 56.37M | -203.56M | 83.41M |
| SaleOfInvestment | 166.92M | 258.50M | 111.59M | 88.91M |
| PurchaseOfInvestment | -160.92M | -202.13M | -315.14M | -5.50M |
| NetBusinessPurchaseAndSale | 0.00 | -6.68M | -610.00K | -15.43M |
| PurchaseOfBusiness | 0.00 | -6.68M | -610.00K | -15.43M |
| NetIntangiblesPurchaseAndSale | 0.00 | -896.00K | -3.10M | -6.70M |
| PurchaseOfIntangibles | 0.00 | -896.00K | -3.10M | -6.70M |
| CapitalExpenditureReported | -6.48M | -8.34M | -21.23M | -13.56M |
| OperatingCashFlow | 38.05M | -18.39M | -25.24M | -19.29M |
| CashFlowFromContinuingOperatingActivities | 38.05M | -18.39M | -25.24M | -19.29M |
| ChangeInWorkingCapital | -102.31M | 106.59M | -14.22M | -40.97M |
| ChangeInOtherWorkingCapital | -187.00K | 566.00K | -215.00K | -1.38M |
| ChangeInOtherCurrentLiabilities | -5.86M | -5.42M | -3.46M | -23.10M |
| ChangeInPayablesAndAccruedExpense | -82.10M | 93.61M | 22.00K | 20.00M |
| ChangeInAccruedExpense | -76.99M | 90.71M | 2.08M | 18.21M |
| ChangeInPayable | -5.11M | 2.90M | -2.05M | 1.79M |
| ChangeInAccountPayable | -5.11M | 2.90M | -2.05M | 1.79M |
| ChangeInPrepaidAssets | 606.00K | 1.77M | -1.05M | -5.14M |
| ChangeInInventory | -1.02M | 54.00K | -2.86M | -6.93M |
| ChangeInReceivables | -13.74M | 16.02M | -6.66M | -24.42M |
| ChangesInAccountReceivables | -13.74M | 16.02M | -6.66M | -24.42M |
| OtherNonCashItems | 931.00K | 568.00K | 727.00K | 298.00K |
| StockBasedCompensation | 66.41M | 49.09M | 46.55M | 36.08M |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | 0.00 | 1.18M | 1.74M |
| AssetImpairmentCharge | 0.00 | 1.00M | 840.00K | 2.44M |
| AmortizationOfSecurities | 621.00K | -4.93M | 390.00K | 1.13M |
| DepreciationAmortizationDepletion | 19.76M | 19.82M | 16.01M | 11.88M |
| DepreciationAndAmortization | 19.76M | 19.82M | 16.01M | 11.88M |
| Depreciation | 19.76M | 19.82M | 16.01M | 11.88M |
| OperatingGainsLosses | 91.00K | -250.00K | -107.00K | -106.00K |
| GainLossOnInvestmentSecurities | -294.00K | -107.00K | -106.00K | |
| NetIncomeFromContinuingOperations | 52.55M | -190.28M | -76.61M | -30.66M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CDNA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|